In a report published Thursday, Jefferies analyst Thomas Wei reiterated a Buy rating on Incyte Corporation INCY, and raised the price target from $36.00 to $44.00.
In the report, Jefferies noted, “Positive overall survival data from RECAP in pancreatic cancer were unexpected and validate the use of Jakafi in solid tumors where Jak2 and/or cachexia may play a role in survival. We are impressed with the OS benefit magnitude in an undisclosed, prespecified subgroup representing 50% of patients. We see the U.S. sales opportunity for pancreatic cancer as $700+m and are increasing our price target by $8 to $44.”
Incyte Corporation closed on Wednesday at $36.04.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in